紫杉醇+铂类+贝伐珠单抗治疗中晚期或复发进展期宫颈癌的有效性及安全性探讨

Efficacy and Safety of Paclitaxel+Platinum+Bevacizumab in the Treatment of Locally Advanced or Recurrent Cervical Cancer

目的分析中晚期或复发进展期宫颈癌患者接受贝伐珠单抗联合紫杉醇以及铂类治疗的有效性和安全性。方法方便选取2021年1月—2022年12月贵州省兴义市人民医院收治的66例中晚期或复发进展期宫颈癌患者为研究对象,依据不同治疗方案分为对照组、观察组,每组33例;对照组给予紫杉醇联合铂类治疗,观察组在对照组基础上给予贝伐珠单抗治疗。比较两组患者临床疗效、免疫指标水平、肿瘤特异性生长因子水平和不良反应发生率。结果观察组临床总有效率为87.88%(29/33),高于对照组的66.67%(22/33),差异有统计学意义(χ^(2)=4.228,P<0.05)。观察组不良反应发生率为6.06%(2/33),低于对照组的24.24%(8/33),差异有统计学意义(χ^(2)=4.243,P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)水平均高于对照组,CD8^(+)、肿瘤特异性生长因子水平低于对照组,差异有统计学意义(P均<0.05)。结论中晚期或复发进展期宫颈癌患者接受贝伐珠单抗联合紫杉醇以及铂类治疗,可以明显改善患者的免疫功能,促进肿瘤特异性生长因子水平下降,有效提升治疗效果,且治疗期间的不良反应较少,安全性较高。

Objective To analyze the efficacy and safety of bevacizumab combined with paclitaxel and platinum in patients with advanced or recurrent cervical cancer.Methods A total of 66 patients with advanced or recurrent cervical cancer treated in Xingyi People's Hospital of Guizhou Province from January 2021 to December 2022 were conveniently selected as the study objects,and were divided into control group and observation group according to different treatment plans,with 33 cases in each group.The control group was given paclitaxel combined with platinum,and the observation group was given bevacizumab on the basis of the control group.The clinical efficacy,immune index level,tumor-specific growth factor level and incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate of the observation group was 87.88%(29/33),which was higher than that of the control group 66.67%(22/33),the difference was statistically significant(χ^(2)=4.228,P<0.05).The incidence of adverse reactions in the observation group was 6.06%(2/33),which was lower than that in the control group 24.24%(8/33),and the difference was statistically significant(χ^(2)=4.243,P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in observation group were higher than those in control group,and the levels of CD8^(+)and tumor-specific growth factor were lower than those in control group,the differences were statistically significant(all P<0.05).Conclusion Treatment with bevacizumab combined with paclitaxel and platinum in patients with advanced or recurrent cervical cancer can significantly improve the immune function of patients,promote the reduction of tumor-specific growth factor levels,effectively improve the therapeutic effect,and have fewer adverse reactions and high safety during treatment.